📄 Cross-examination of Dr. John Gerdes (afternoon, part 1) — Thursday, August 3, 1995
Address:
C:\DEPT103\CRIMINAL\1995\AUG\3\CROSS-EXAMINATION-OF-DR-JOHN-G.DOC
TRIAL
▲ Day 128 of 167

Cross-examination of Dr. John Gerdes (afternoon, part 1)

Witness: Dr. John Gerdes
Examiner: George Clarke
Called by: Defense • Date: Thursday, August 3, 1995 • Utterances: 694
George Clarke continued cross-examining defense DNA contamination expert Dr. John Gerdes, methodically challenging the breadth of his expertise and the consistency of his opinions. Clarke established that Gerdes had run fewer than 100 polymarker samples and had never attended a single forensic DNA presentation, then walked through multiple peer-reviewed publications validating DQ-Alpha, PM, and D1S80 typing — each of which Gerdes dismissed as a mere 'demonstration paper.' Clarke also exposed that Gerdes had testified a forensic protocol required specific contamination-prevention steps, then forced him to concede no such protocol actually exists, and that Gerdes had never reviewed the serological evidence in the case despite its relevance to his contamination theory.
1 MR. CLARKE:

Dr. Gerdes, just going back for a moment, if I can, you described this morning how as far as your paternity testing in your lab that you use databases to calculate some numbers to describe how rare a match is between an alleged father, let's say, and a child, correct?

2 DR. GERDES:

Using a different type of statistics, that's correct.

3 MR. CLARKE:

As far as that method is concerned, do you use databases to make that calculation?

4 DR. GERDES:

Yes.

5 MR. CLARKE:

Where are the databases from that you use in your laboratory for that purpose?

6 MR. SCHECK:

Objection, beyond the scope.

7 THE COURT:

Overruled.

8 DR. GERDES:

The database we use is obtained from life codes.

9 MR. CLARKE:

Is life codes a forensic laboratory?

10 DR. GERDES:

They do forensic testing, yes.

11 MR. CLARKE:

Do you use any other database sets other than those from life codes?

12 DR. GERDES:

We have our own database as well, but we generally use the life codes database.

13 MR. CLARKE:

Now, I would like to shift your attention, if I could, to polymarkers. We discussed a little bit earlier that a polymarker consists of more than one genetic marker; is that right?

14 DR. GERDES:

That's correct.

15 MR. CLARKE:

How many does it consist of?

16 DR. GERDES:

Five.

17 MR. CLARKE:

As far as this polymarker is concerned, is it also a test that is used using a kit?

18 DR. GERDES:

Yes, it is.

19 MR. CLARKE:

And does Roche in fact manufacture, or through Perkin Elmer, market the particular kit that is used to type the polymarkers?

20 DR. GERDES:

They do.

21 MR. CLARKE:

As far as your own personal experience have you used that particular polymarker kit?

22 DR. GERDES:

We haven't used it for any case work, but I have had an occasion to run one kit's worth which is a hundred samples.

23 MR. CLARKE:

So you have used one kit and you have run a hundred samples through the polymarkers?

24 DR. GERDES:

I'm not even sure we ran all of them, but we have run at least half that amount I would say.

25 MR. CLARKE:

So something less than a hundred samples?

26 DR. GERDES:

Something less than a hundred.

27 MR. CLARKE:

Does that constitute then your personal familiarity with the polymarker kit?

28 DR. GERDES:

As far as actually running it, yes.

29 MR. CLARKE:

You haven't done any other testing using any other techniques for these five genetic markers, have you?

30 DR. GERDES:

No.

31 MR. CLARKE:

Other than the one time with the kit?

32 DR. GERDES:

No.

33 MR. CLARKE:

As far as presentations, and this would be lectures, have you attended any lectures or presentations reporting information about validating the use of the polymarker in forensics?

34 DR. GERDES:

I haven't attended any lectures or meetings. Is that what you are saying?

35 MR. CLARKE:

Yes, any presentations?

36 DR. GERDES:

No.

37 MR. CLARKE:

This particular set of five genetic markers, are they all amplified at the same time using this thermalcycler, the machine that actually copies the DNA over and over again?

38 DR. GERDES:

Yes.

39 MR. CLARKE:

Is there anything unique about that to forensics as far as multiplying more than one marker at the same time?

40 DR. GERDES:

It is done with genetic applications as well.

41 MR. CLARKE:

So in other words, this amplifying a number of markers at the same time is also used in disease diagnosis, correct?

42 DR. GERDES:

Yes.

43 MR. CLARKE:

That would be a clinical use?

44 DR. GERDES:

Yes.

45 MR. CLARKE:

As far as these markers themselves, are they simply five more genetic markers that are used to type samples in a forensic case?

46 DR. GERDES:

Yes.

47 MR. CLARKE:

In other words, there is nothing unique about them in comparison to DQ-Alpha?

48 DR. GERDES:

Other than they are different gene--different genes.

49 MR. CLARKE:

And then in that same vein I would like to turn your attention to D1S80. Have you ever tested that particular marker in your laboratory?

50 DR. GERDES:

No.

51 MR. CLARKE:

Have you bought or used the kit--well, let me rephrase. As far as this particular marker, is it also tested in kit form commonly?

52 DR. GERDES:

Yes.

53 MR. CLARKE:

And is that again another kit marketed by Perkin Elmer, manufactured by Roche?

54 DR. GERDES:

It is.

55 MR. CLARKE:

Have you ever bought or used that particular kit?

56 DR. GERDES:

No.

57 MR. CLARKE:

Is that again simply another marker that is available for use in terms of being another particular genetic marker in addition to DQ-Alpha and the five polymarkers?

58 DR. GERDES:

Yes.

59 MR. CLARKE:

Is there anything unique about D1S80 that makes it a good or bad marker?

60 DR. GERDES:

Umm, that particular marker is a little different. It doesn't use the dot-blot detection methodology. It is a little different detection and that is the only major difference.

61 MR. CLARKE:

So in other words, the way that the marker is actually typed is a little bit different than DQ-Alpha and the polymarkers, right?

62 DR. GERDES:

That's correct.

63 MR. CLARKE:

Is it actually read--and you may have read testimony and descriptions of D1S80 results. Is it actually read a little more like the RFLP method?

64 DR. GERDES:

It is.

65 MR. CLARKE:

And there is nothing wrong with utilizing that particular method of telling different types instead using, let's say, a dot-blotting technique?

66 MR. SCHECK:

Objection to the wrong--vague question, calls for speculation.

67 THE COURT:

Sustained. Rephrase the question.

68 MR. CLARKE:

As far as typing D1S80 by this method, that is more like RFLP typing, is there anything unreliable about that technique?

69 DR. GERDES:

All of these are--again, the point is that they are all PCR-based tests, they are all susceptible to the dangers because of the sensitivity of the test.

70 MR. CLARKE:

Well, just referring you now to the way that it is typed, setting aside your concerns that you've expressed, is there anything different about typing it by the more RFLP type banding pattern method versus simply dot-blotting it?

71 DR. GERDES:

Well, it is different. There is nothing wrong with it, if that is what you are--as far as that type of detection system.

72 MR. CLARKE:

Have you ever--and you have described--let me ask one question first. You've described the fact that in your laboratory you use was it FDA-approved tests?

73 DR. GERDES:

The clinical testing the majority of them are FDA approved, yes.

74 MR. CLARKE:

Okay. Is there anything about FDA approval that means you either can or can't use it in a clinical setting?

75 DR. GERDES:

The regulation is in terms of being able to market a kit for the purpose of clinical testing. The FDA--a clinical lab can run a test that is not FDA approved, they have to just do their own validation and satisfy CLIA that that has been done.

76 MR. CLARKE:

Do you do any testing in your laboratory using techniques that are not FDA approved?

77 DR. GERDES:

Yes.

78 MR. CLARKE:

For example, what?

79 DR. GERDES:

The CMV tests for PCR.

80 MR. CLARKE:

And this is a test that you use in case work with samples that come into the lab to determine whether the CMV virus is present at sufficient levels that some medical danger may exist?

81 DR. GERDES:

That's correct.

82 MR. CLARKE:

Are there any other tests that you use in your laboratory that are not FDA approved?

83 DR. GERDES:

None that come to mind at the moment.

84 MR. CLARKE:

I may--I don't believe I have asked. As far as the CMV testing itself, what percentage roughly of the case work in your laboratory does it constitute?

85 DR. GERDES:

You mean in terms of HLA and everything else?

86 MR. CLARKE:

Yes, of case work?

87 DR. GERDES:

Less than ten percent.

88 MR. CLARKE:

Is it your testimony that unless a test is FDA approved it shouldn't be used?

89 DR. GERDES:

No. The point behind FDA approval is it is generally considered as the ultimate validation for a clinical-based test. That doesn't mean that testing can't be done just because it isn't FDA approved.

90 MR. CLARKE:

And as far as the forensic tests used in this case, they don't have FDA approval, correct?

91 DR. GERDES:

The FDA does not approve forensic-based testing.

92 MR. CLARKE:

The absence of that FDA approval does not mean that the tests are unreliable simply because they don't have FDA approval, correct?

93 DR. GERDES:

That's correct.

94 MR. CLARKE:

Is it correct, Dr. Gerdes, that one general measure of scientific acceptability of a test is the number of labs who are using the technology and cross-checking one another?

95 DR. GERDES:

That is one way of looking at it.

96 MR. CLARKE:

Is it also correct that another measure of scientific acceptability of a test is the number of publications that have stated in fact that the test is reliable and it can be reproduced?

97 DR. GERDES:

That would be one aspect.

98 MR. CLARKE:

Are you aware of any publications that demonstrate that if properly used the DQ-Alpha typing kit produces proper, accurate and reliable results on forensic samples?

99 DR. GERDES:

There are publications in the forensic literature that state that.

100 MR. CLARKE:

Are you aware of any publications that demonstrate to the contrary?

101 DR. GERDES:

As I mentioned earlier, there are numerous publications that deal with and discuss the contamination issues, the sensitivity issues, that we've gone over a number of times here. None of them will have--have come straight out and said that you shouldn't use the kit.

102 MR. CLARKE:

Are there any publications demonstrating the scientific unacceptability of using the polymarker kit in forensic samples?

103 DR. GERDES:

No.

104 MR. CLARKE:

Are there any publications demonstrating the fact that use of the D1S80 typing kit produces unreliable and inaccurate results?

105 DR. GERDES:

Again, there are numerous publications that discuss the problems. None of them come right out and say you shouldn't use the kit.

106 MR. CLARKE:

I would like to talk with you a moment about peer review. You are familiar with the term "Peer review"?

107 DR. GERDES:

Yes.

108 MR. CLARKE:

What does "Peer review" mean?

109 DR. GERDES:

It is a process where if you are going to publish an article, the article is sent to a number of reviewers who are your peers, that is, people who have an equivalent training, and they will evaluate that, criticize it, make suggestions, and before the article can be published it has to be approved by a majority of those peers.

110 MR. CLARKE:

The peer review process is an important one as far as scientific literature, correct?

111 DR. GERDES:

It is important in academics.

112 MR. CLARKE:

Is it in fact one of the ways the scientific community validates a technique to determine its accuracy and reliability?

113 DR. GERDES:

Not necessarily. I mean, you are not validating the technique. You are just basically cross-checking with a number of different--a number of your peers to see if your statements are defensible scientifically.

114 MR. CLARKE:

Doesn't this publication process allow other scientists to look at the findings of scientists who publish this material to be able to evaluate whether or not a technique in fact should be used?

115 DR. GERDES:

They--they--the publication usually is not strictly being offered for the purpose of a flat statement that a particular thing can be used. I mean, it is generally a scientific documentation of observations.

116 MR. CLARKE:

Incidentally--I'm sorry.

117 DR. GERDES:

And the peers will look at these observations and see if they have been analyzed in a scientific manner and whether the conclusions are reasonable.

118 MR. CLARKE:

You mention the fact that there were publications that talk about contamination involving PCR, correct?

119 DR. GERDES:

Yes.

120 MR. CLARKE:

Those publications serve as warnings to individuals who perform the typing process so that they can incorporate what that publication is showing into their own wealth of knowledge; is that correct?

121 DR. GERDES:

Well, it depends on the publication. That is too general of a statement. There are publications which are just blind trials, if you will, where--on PCR where the kit was sent, and then there was an observation of contamination. It was simply reported that so many labs had contamination.

122 MR. CLARKE:

Are you, in your opinion, familiar with the DQ-Alpha forensic typing literature?

123 DR. GERDES:

Yes.

124 MR. CLARKE:

That is extensive, isn't it?

125 DR. GERDES:

Fairly, yes.

126 MR. CLARKE:

I'm sorry. May I have a moment, your Honor?

127 (Discussion held off the record between the Deputy District Attorneys.)
128 MR. CLARKE:

Dr. Gerdes, are you familiar with a book entitled "PCR technology"?

129 DR. GERDES:

Yes.

130 MR. CLARKE:

And are you familiar with who the editor of that book is?

131 DR. GERDES:

I believe it is Henry Erlich.

132 MR. CLARKE:

Who is Henry Erlich?

133 DR. GERDES:

Henry Erlich is an individual who was at Cetus at the time this technology was being developed at that particular company and has done work in the area of HLA typing.

134 MR. CLARKE:

And HLA--I'm sorry, go ahead.

135 DR. GERDES:

HLA typing.

136 MR. CLARKE:

HLA again, not only DQ-Alpha, but also at least one of the markers typed in your laboratory?

137 DR. GERDES:

Yes, that whole gene complex.

138 MR. CLARKE:

Have you read that book?

139 DR. GERDES:

I have read most of it.

140 MR. CLARKE:

There is a chapter in that book entitled "Applications of PCR to the analysis of biological evidence." Are you familiar with that?

141 DR. GERDES:

Yes.

142 MR. CLARKE:

Have you read that chapter?

143 DR. GERDES:

Yes.

144 MR. CLARKE:

Do you recall who the authors of that chapter are?

145 DR. GERDES:

I believe Henry Erlich is one of the authors if you are referring to the same one. Is that what you are referring to?

146 MR. CLARKE:

Yes.

147 DR. GERDES:

I don't recall the other authors.

148 MR. CLARKE:

Is Cecelia von Beroldingen an author?

149 DR. GERDES:

Yes.

150 MR. CLARKE:

Russell Higuchi?

151 DR. GERDES:

Yes.

152 MR. CLARKE:

George Sensabaugh?

153 DR. GERDES:

Yes.

154 MR. CLARKE:

And Edward Blake?

155 DR. GERDES:

Yes.

156 MR. CLARKE:

With regard to that article, in your view that is an article demonstrating the validity of PCR forensic typing using the DQ-Alpha marker?

157 DR. GERDES:

I think it discusses the--the issues. I don't think it justifies the validity based on that article. It is basically a review article.

158 MR. CLARKE:

Okay. Does it discuss in fact the uses of PCR to type samples using markers including DQ-Alpha?

159 DR. GERDES:

It does.

160 MR. CLARKE:

Are you also familiar with an article entitled "Polymerase chain reaction PCR amplification and human leukocyte antigen HLA DQ-Alpha oligonucleotide typing on biological evidence samples: Casework experience."

161 DR. GERDES:

Yes, I am familiar with that.

162 MR. CLARKE:

And you have read that particular publication?

163 DR. GERDES:

That is Ed Blake's article, correct?

164 MR. CLARKE:

Yes. Are there other authors as well?

165 DR. GERDES:

Yes.

166 MR. CLARKE:

And do you rely on that article in terms of any of the opinions that you've offered in this court?

167 DR. GERDES:

No.

168 MR. CLARKE:

Do you in fact reject what is written in that particular publication?

169 DR. GERDES:

I consider that publication a one-side--one-sided slant on the cases. It discusses a number of cases, several of which I have been involved with, where there were highly contested issues which are not discussed in that article.

170 (Discussion held off the record between the Deputy District Attorneys.)
171 MR. CLARKE:

Dr. Gerdes, with regard to these publications about DQ-Alpha--and again, there are a large number of them, correct?

172 DR. GERDES:

Yes.

173 MR. CLARKE:

Do you rely on any of those publications that in fact demonstrate this reliability of the DQ-Alpha typing process?

174 MR. SCHECK:

Objection, vague.

175 THE COURT:

Overruled.

176 DR. GERDES:

I'm familiar with those publications. I think it is a misstatement to say I rely upon them.

177 MR. CLARKE:

Well, do you in fact reject their findings about reliability?

178 DR. GERDES:

I accept their observations of problems and discussions of those in certain instances. I disagree with certain other statements and I disagree with their conclusions in some instances. It is very general. You would have to take them one at a time.

179 MR. CLARKE:

Okay. Are you familiar with a publication entitled "DNA typing from single hairs"?

180 DR. GERDES:

Yes.

181 MR. CLARKE:

By Russell Higuchi and other authors as well?

182 DR. GERDES:

Yes.

183 MR. CLARKE:

Have you read that particular publication?

184 DR. GERDES:

Yes, I have.

185 MR. CLARKE:

In terms of its findings of reliability do you reject the author's conclusions?

186 MR. SCHECK:

Objection, too vague.

187 THE COURT:

Overruled.

188 DR. GERDES:

Well, that particular paper is simply a demonstration paper. It is a paper that the overall bottom line is that it shows that it is possible to obtain a DNA result on a single hair, and that part of the paper I don't disagree with. That certainly is possible. It doesn't discuss the difficulties that there would be in taking that technology and using it on a routine basis in crime scenes.

189 MR. CLARKE:

Are you familiar with a publication entitled "Genetic markers in human bone: I, deoxyribonucleic acid DNA analysis" by Henry Lee and others?

190 DR. GERDES:

I am familiar with that.

191 MR. CLARKE:

Have you read that publication?

192 DR. GERDES:

Yes.

193 MR. CLARKE:

Do the authors of that publication include individuals at Cellmark diagnostics?

194 DR. GERDES:

I believe so.

195 MR. CLARKE:

Does the name George Herrin sound familiar?

196 DR. GERDES:

Yes.

197 MR. CLARKE:

And to your knowledge was that individual, Mr. Herrin, Dr. Herrin, actually at Cellmark diagnostics at one time?

198 DR. GERDES:

I believe so.

199 MR. CLARKE:

Are you familiar with the name Dr. Daniel garner?

200 DR. GERDES:

Yes.

201 MR. CLARKE:

Who is he?

202 DR. GERDES:

He is--I'm not sure what his exact title is. He is from the FBI and is involved in the DNA--the Department of DNA Testing or whatever they call their department.

203 MR. CLARKE:

Actually Dr. Garner is at Cellmark diagnostics, is he not?

204 DR. GERDES:

I'm sorry. I'm thinking of--yes, okay.

205 MR. CLARKE:

With respect to this publication do you reject Dr. Lee and the other author's conclusions about the reliability of DQ-Alpha typing?

206 DR. GERDES:

Again, I mean that is a demonstration paper that shows that you can use this technique under controlled conditions to identify individuals based on bone. It doesn't discuss the general problems that can occur, the routine application in labs, and it doesn't discuss the aspect of determining whether a specific laboratory may have significant contamination problems which would render those demonstrations of capability invalid.

207 MR. CLARKE:

One more, if I might, Dr. Gerdes. Are you familiar with a publication by the federal Bureau of Investigation entitled "Validation studies on the analysis of the HLA DQ-Alpha locus using the polymerase chain reaction" by Dr. Comey and Dr. Bruce Budowle?

208 DR. GERDES:

I am familiar with that.

209 MR. CLARKE:

Have you read that particular publication?

210 DR. GERDES:

I have.

211 MR. CLARKE:

That publication deals with reliability of DQ-Alpha typing, correct?

212 DR. GERDES:

It does.

213 MR. CLARKE:

That publication also deals with contamination and its effects on typing using forensic samples?

214 DR. GERDES:

Again it is a demonstration paper. What they dealt with in that paper in terms of contamination is one experiment where five tubes were opened on a bench top. They scratched their head over the tubes, closed them up and showed there was no contamination. That is a demonstration. Demonstrates that under those limited number of samples they did not get contamination. From that they conclude that contamination is not an issue. That I disagree with.

215 MR. CLARKE:

We have just discussed approximately five publications; is that right?

216 DR. GERDES:

Yes.

217 MR. CLARKE:

There are many more, are there not?

218 DR. GERDES:

Yes, and most of them are, as I said, demonstration papers that show under controlled conditions and in specific instances in particular laboratories it is possible to obtain a type.

219 MR. SCHECK:

Your Honor, may I--the last article that Mr. Clarke referred to I believe has an exhibit number. It came up in the testimony of Mr. Sims, and I don't have it right here, but I think it would clarify the record if we could identify it by this number so that we can flag it with the other testimony.

220 THE COURT:

It is identified by its title and authors.

221 (Discussion held off the record between the Deputy District Attorneys.)
222 MR. CLARKE:

Dr. Gerdes, you referred to these largely as demonstration papers; is that correct?

223 DR. GERDES:

That is what I consider them.

224 MR. CLARKE:

Have you ever done such a demonstration paper as far as this particular forensic area of typing is concerned?

225 MR. SCHECK:

Objection, asked and answered.

226 THE COURT:

Overruled.

227 DR. GERDES:

No, I haven't published in the forensic area.

KEY QUOTE
228 MR. CLARKE:

Now, I would like to shift your attention, if I could, to the polymarkers. I believe we discussed those a few moments ago. As far as that particular set of five genetic markers, there are similar publications, are there not, in the scientific literature?

229 DR. GERDES:

There are similar demonstration papers. It is a newer system so there are fewer in number.

230 MR. CLARKE:

Are you familiar, for example, with a publication entitled "Evaluation of the amplitype PM DNA test system on forensic case samples"?

231 DR. GERDES:

Who is the author on that?

232 MR. CLARKE:

George Herrin, Nicola Fildes and Rebecca Reynolds?

233 DR. GERDES:

Yes, I am familiar with that article.

234 MR. CLARKE:

Incidentally, PM, is that short for polymarker?

235 DR. GERDES:

Yes.

236 MR. CLARKE:

With respect to that article have you read it?

237 DR. GERDES:

Yes.

238 MR. CLARKE:

With respect to this article also do you reject its findings and conclusions about reliability of the PM typing system?

239 DR. GERDES:

I believe they did 16 samples there. It is a demonstration paper and it is interesting that in one of those 16 samples they had a chance match.

240 MR. CLARKE:

Is this another paper that you consider a demonstration paper?

241 DR. GERDES:

Yes.

242 MR. CLARKE:

In your opinion is this a paper then that does not demonstrate the accuracy and reliability of using the polymarker typing kit on forensic case samples?

243 DR. GERDES:

Well, I think the analogy here that might clarify this whole thing is basically if I--if you have a clinical kit that someone is using, there may have been some publication as far as the use of that kit, but the ultimate test of any kit, of any method, is how it is used in the field. It is just like products. Just because you put a product on the market and someone says that is a good product, it doesn't mean it is a good product until you've had a chance to look at a large number of individuals who use that product, and if it starts to have flaws, those become apparent. And it is a similar thing in forensics or anything else.

244 MR. CLARKE:

What about when many laboratories use the technique and they r each the same conclusions as the authors, does your opinion still hold true under those circumstances?

245 DR. GERDES:

In my opinion we haven't reached that stage where there has been enough testimony and discussion and in-depth analysis of the specific problem of contamination and how that can create errors in a blinded fashion in the forensic community.

246 MR. CLARKE:

In your view courtroom testimony is important in establishing scientific validity?

247 DR. GERDES:

In my view that is--that is like the consumer report. It is what--what--how is it working in the field? We have done these demonstration papers that say it is possible. Now we put it out into the field, we put it on the market. How is it working? What is the feedback from the consumer?

248 MR. CLARKE:

I'm sorry, could I have a moment, your Honor?

249 (Discussion held off the record between the Deputy District Attorneys.)
250 MR. CLARKE:

Incidentally, when you refer, Dr. Gerdes, to the first polymarker article, the one we just discussed as being seven laboratories, were you speaking of a different publication?

251 DR. GERDES:

Excuse me?

252 MR. CLARKE:

When you referred to this paper by George Herrin the article on evaluation of the PM system, were you mistaking that paper for another as far as the seven laboratories?

253 DR. GERDES:

Yes. If you can let me look at the paper, I can answer that question.

254 MR. SCHECK:

Your Honor, I would ask now that these be marked so that we can know which ones they are.

255 THE COURT:

Overruled. Why don't you show it to him.

256 MR. SCHECK:

They have shown it to the witness.

257 MR. CLARKE:

Sure. May I approach the witness, your Honor?

258 THE COURT:

You may.

259 (Brief pause.)
260 DR. GERDES:

No. That is the paper I was referring to. In terms of the false match you mean?

261 MR. CLARKE:

I'm sorry?

262 DR. GERDES:

In terms of the false match?

263 MR. CLARKE:

No, you mentioned seven laboratories?

264 DR. GERDES:

No, I didn't. I said several.

265 MR. CLARKE:

Oh, several, I'm sorry. All right. Are you also familiar with a publication entitled "Consistency and reproducibility of amplitype PM results between seven laboratories: Field trial results"?

266 DR. GERDES:

I am familiar with that.

267 MR. CLARKE:

By Nicola Fildes and Rebecca Reynolds again?

268 DR. GERDES:

Yes.

269 MR. CLARKE:

Have you read that document?

270 DR. GERDES:

Yes.

271 MR. CLARKE:

And do you reject its conclusion about reliability of the PM typing system?

272 DR. GERDES:

Again, it is a demonstration paper.

KEY QUOTE
273 MR. CLARKE:

As you have used the term earlier?

274 DR. GERDES:

Yes.

275 MR. CLARKE:

And lastly, in this area, are you familiar with "Amplitype PM and HLA DQ-Alpha typing from pap smear, semen smear and postcoital slides" by Renee Roy--Dr. Renee Roy and Dr. Rebecca Reynolds?

276 DR. GERDES:

Could I see that?

277 MR. CLARKE:

Sure.

278 DR. GERDES:

I don't believe I have seen this paper.

279 MR. CLARKE:

All right. To your knowledge, other than the publications that I have just described, are there others demonstrating the reliability of PM typing on forensic samples?

280 DR. GERDES:

Umm, there are--there are other demonstration papers that--with regard to the use of the polymarker system.

281 MR. CLARKE:

And you have used that term?

282 DR. GERDES:

Yes.

283 MR. CLARKE:

Can you tell us approximately how many laboratories type the polymarkers in forensic casework?

284 DR. GERDES:

Umm, there are probably hundreds of labs. I don't know an exact figure.

285 MR. CLARKE:

I'm sorry, hundreds?

286 DR. GERDES:

Yes.

287 MR. CLARKE:

Incidentally, all of the publications that I have shown you or described the title that we discussed, with the exception of the last one that you are unfamiliar with, they are all from peer-reviewed scientific publications, correct?

288 DR. GERDES:

That's correct.

289 MR. CLARKE:

And actually the last particular publication I showed you was also in a peer review publication; is that correct?

290 DR. GERDES:

Yes.

291 MR. CLARKE:

And then lastly, with regard to the D1S80 system, are you familiar with similar publications demonstrating the reliability of that particular marker's use in forensics?

292 DR. GERDES:

There are similar demonstration papers discussing the capability of that system to produce a type.

293 MR. CLARKE:

Without going through each of them, would your answers then be the same with regard to those publications, that they are in fact demonstration papers only?

294 DR. GERDES:

Yes.

295 MR. CLARKE:

In your view they in no manner establish the reliability of D1S80 typing on forensic casework?

296 DR. GERDES:

They do not, as I mentioned before. My opinion is the product has to be used to an adequate degree and evaluated in a critical manner, in a critical blinded manner, before you can really determine the errors that are possible with this system.

297 MR. CLARKE:

Can you give us an estimate, for instance, how many cases you think DQ-Alpha typing has been used in in forensic casework just in this country?

298 DR. GERDES:

I'm not aware of how many. I'm sure it is probably in the hundreds.

299 MR. CLARKE:

With--and I believe you described earlier over 100 laboratories use the technique; is that correct?

300 DR. GERDES:

So it is probably even in the thousands.

301 MR. CLARKE:

Isn't it more likely in the many thousands?

302 THE COURT:

That is vague.

303 DR. GERDES:

I--

304 MR. CLARKE:

I don't believe I asked you about D1S80. Are you familiar with approximately how many laboratories use it in casework?

305 DR. GERDES:

Again, that is a newer system. It would be fewer than the DQ-Alpha, but most of the labs who have set up PCR for one system fairly rapidly add the next one.

306 MR. CLARKE:

As far as all of these markers, DQ-Alpha, polymarker and D1S80, is it correct that there have been many presentations about their use in forensic casework, and I'm referring to meetings, lectures, symposia and so forth?

307 DR. GERDES:

Yes.

308 MR. CLARKE:

That is a fairly common event--let me rephrase that if I may. That is a fairly common manner of the scientific community, discussing work, whether in forensics or clinical work, that is, presentations and symposia?

309 DR. GERDES:

Yes.

310 MR. CLARKE:

Do those presentations, conferences and symposia play an important role in not only disseminating but also discussing scientific techniques?

311 DR. GERDES:

Umm, yes.

312 MR. CLARKE:

With regard to polymarker and D1S80 and DQ-Alpha, have you attended any such meetings?

313 DR. GERDES:

No.

314 MR. CLARKE:

You have described how the DQ-Alpha marker was the first marker used following PCR amplification in forensics, correct?

315 DR. GERDES:

Correct.

316 MR. CLARKE:

Are you aware of when that began? When was the first case using PCR DQ-Alpha?

317 DR. GERDES:

I know when the kit was released, approximately, which was in 1990, and I believe that there was a single individual doing typing probably three, four years before that.

318 MR. CLARKE:

Would 1986 be approximately the time of this individual doing that work?

319 DR. GERDES:

That might be the case. PCR was first published in 1985.

320 MR. CLARKE:

This individual--I'm sorry.

321 DR. GERDES:

So--and this individual happened to be working in the same area where the method was developed.

322 MR. CLARKE:

Who was that individual?

323 DR. GERDES:

Ed Blake.

324 MR. CLARKE:

Is it correct or it is correct, isn't it, that when you add more markers, in other words, from DQ-Alpha adding additional markers, like PM and D1S80, that that adding of more markers allows the analyst to cross-check results on individual samples?

325 DR. GERDES:

It allows cross-checking as long as you have totally ruled out the possibility of cross-contamination, because in the case of cross-contamination, remember, you can look at as many markers as you want to and the error is caused by that physical cross-transfer and therefore that type of contamination would not be detected.

326 MR. CLARKE:

Like your clinical use where more markers provide you more information, isn't it also true that adding more markers in a forensic context increases the probabilities that a sample came from one person to the exclusion of others?

327 DR. GERDES:

That's true.

328 MR. CLARKE:

You have previously--I'm sorry--previously said you would like to see more forensic markers added to DQ-Alpha, correct?

329 DR. GERDES:

I think it does add to the capability of detecting the other types of contaminants, which are the--the contaminants due to amplification product carry-over, for instance.

330 MR. CLARKE:

In other words, by adding additional markers you increase your chances of detecting contamination?

331 DR. GERDES:

That's true.

332 MR. CLARKE:

And you so testified in 1990 about it would be good if more markers were added to DQ-Alpha?

333 DR. GERDES:

That's true.

334 MR. CLARKE:

Since that time six additional markers have been added that are routinely used in forensic casework, correct?

335 DR. GERDES:

Correct.

336 MR. CLARKE:

Those six markers that were added to DQ-Alpha were all used in this case; is that right?

337 DR. GERDES:

That's correct. Since that time it has become more abundantly obvious to me that the type of cross-contamination--

338 MR. CLARKE:

Objection, move to strike, your Honor.

339 THE COURT:

Nonresponsive, you are right. Stricken.

340 MR. CLARKE:

As you add more markers, don't you increase the ability to resolve ambiguities or uncertainties about typing results?

341 DR. GERDES:

You increase the capability of resolving ambiguities due to amplification carry-over, that kind of contamination, yes.

342 MR. CLARKE:

Incidentally, you have described in your laboratory about the use of PCR with some sample and also using other techniques, serologic techniques?

343 DR. GERDES:

We do both kind of techniques in our lab, yes.

344 MR. CLARKE:

Well, what I'm really directing my question to is are there any samples that you use PCR with that you will type using serologic techniques?

345 DR. GERDES:

Yes.

346 MR. CLARKE:

Why do you use both of those tests on a given sample?

347 DR. GERDES:

Well, for the specific cases I am thinking of they give you different information, so for instance, if I want to look at a serological marker for cytomegalovirus, that tells me which individual is at higher risk of having this virus become a problem after they receive their transplant. Someone who has antibody to that before they have their transplant is going to be--they have been exposed to that virus in the past, so that gives me information that that is a patient maybe we should follow more closely by PCR to look directly for the virus after the transplant.

348 MR. CLARKE:

Are there any instances in which you use a serologic technique and a PCR technique as a cross-check in any manner?

349 DR. GERDES:

Not at the present time.

350 MR. CLARKE:

Was that true in the past?

351 DR. GERDES:

No.

352 MR. CLARKE:

As far as this use of multiple markers--and you have described the fact that in this case, at least with many samples, seven PCR markers were used, correct?

353 DR. GERDES:

Yes.

354 MR. CLARKE:

Is it correct that serologic techniques that are also used on a given sample, that also adds more markers to act as a cross-check, doesn't it?

355 DR. GERDES:

Well, you are really again looking at something different. You are looking at an antibody which tells you--if we are talking about an infectious agent, that tells you that that person had been exposed in the past. If they are antibody positive--let's take HIV as an example. If they are antibody positive and then you were to do a PCR and you found the presence of the genome of HIV, then that would confirm the antibody test.

356 MR. CLARKE:

You are familiar with the fact that in this case not only was DNA used but also conventional serological techniques; isn't that right?

357 DR. GERDES:

Yes.

358 MR. CLARKE:

Did you examine those conventional serological techniques?

359 DR. GERDES:

No.

360 MR. CLARKE:

If conventional serological techniques were used in this case and results were obtained from stains from genetic markers other than the DNA markers, don't those constitute additional cross-checks of results?

361 DR. GERDES:

Yes.

362 MR. CLARKE:

But you didn't look at any of the serological results?

363 DR. GERDES:

No.

364 MR. CLARKE:

Did you believe it was important to know about any such results?

365 DR. GERDES:

No. My function was to look simply at the science involved and the data involved in PCR.

KEY QUOTE
366 MR. CLARKE:

Did any member of the Defense ever discuss with you the existence of serological results in this case?

367 DR. GERDES:

No.

368 MR. CLARKE:

Is that a factor in your opinion would have any effect whatsoever on any of the opinions you've rendered in this case?

369 DR. GERDES:

No, because my opinions are as to the scientific reliability of the PCR-based testing and the chances of error due to cross-contamination.

370 MR. CLARKE:

Is it your testimony that such cross-contamination would necessarily never be detected by serological techniques?

371 DR. GERDES:

I think it is highly unlikely because PCR is the most sensitive method possible and those items would have very little amount of material.

372 MR. CLARKE:

Well, you have raised the possibility that some of the Bundy blood drops may have been cross-contaminated by other stains; is that correct?

373 DR. GERDES:

Yes.

374 MR. CLARKE:

One of those stains that you've discussed as being possibly cross-contaminated by other material was item no. 52; isn't that correct?

375 DR. GERDES:

That's right.

376 MR. CLARKE:

The amount of DNA in that sample is higher than it is in other blood drops at the Bundy scene, correct; 47, 48, 49 and 50?

377 DR. GERDES:

52 has approximately 25 nanograms, or I'm not sure what the total yield was, but it has more.

378 MR. CLARKE:

You discussed yesterday the fact that the recommended minimum amount to be used in, for instance, the Roche DQ-Alpha kit, adds two nanograms, correct?

379 DR. GERDES:

Correct.

380 MR. CLARKE:

Results are obtained with less than two nanograms, aren't they?

381 DR. GERDES:

It depends on how much lower than that, but you can, yes.

382 MR. CLARKE:

Going back to the serological techniques, as a scientist wouldn't you want to know all the scientific results on a given bloodstain if you were looking at a bloodstain case?

383 DR. GERDES:

It is not my job to look at this entire case. It was my job to evaluate the reliability of PCR-based DNA testing as an independent piece of evidence.

384 MR. CLARKE:

If you were a serological expert and you were asked to review results on bloodstains from a crime scene, would you want to know about DNA results?

385 DR. GERDES:

It depends upon whether I was an expert or asked to be an expert on whatever area. I would think that that would be crossing areas of expertise.

386 MR. CLARKE:

Dr. Gerdes--

387 DR. GERDES:

I don't have any--any expertise in serological testing.

388 MR. CLARKE:

Dr. Gerdes, aren't all of the results on these bloodstains important to evaluate what happened?

389 DR. GERDES:

I'm sure they are.

390 (Discussion held off the record between the Deputy District Attorneys.)
391 MR. CLARKE:

In your view is that good science, not to know all the results?

392 DR. GERDES:

In my view the way a criminal case should be conducted, if there is scientific evidence involved, you should obtain the expert with the most expertise in every specific type of testing and it is up to someone else in the case that is not a scientist to evaluate the meaning of that. It is basically up to the jury to evaluate--as all of those experts come forward and provide their testimony, it is up to the jury to decide how these pieces fit together. I'm only talking about one piece of this puzzle.

393 MR. CLARKE:

Who did you discuss the serological results with?

394 DR. GERDES:

I didn't.

395 MR. CLARKE:

Did you have any knowledge of them even existing?

396 DR. GERDES:

Well, I've heard things on TV, but I have no knowledge or access to specific testing.

397 MR. CLARKE:

Once you heard them on TV, did you feel that there was any need whatsoever to find out what they were?

398 DR. GERDES:

Again, my evaluation is of the PCR-based DNA testing.

399 (Discussion held off the record between the Deputy District Attorneys.)
400 MR. CLARKE:

With respect to this area of cross-contamination, is it your testimony that contamination wouldn't be picked up by serological techniques?

401 DR. GERDES:

It depends on the specimen, but I think if it is a specimen with very small amounts, the PCR technique is more sensitive than most serological techniques.

402 (Discussion held off the record between the Deputy District Attorneys.)
403 MR. CLARKE:

Objection, move to strike. Nonresponsive.

404 THE COURT:

Overruled. Overruled.

405 (Discussion held off the record between the Deputy District Attorneys.)
406 MR. CLARKE:

All right. Dr. Gerdes, you have described various forms of contamination in your view; is that correct?

407 DR. GERDES:

Yes.

408 MR. CLARKE:

One of those forms was cross-contamination?

409 DR. GERDES:

That's correct.

410 MR. CLARKE:

One of those forms was carry-over contamination?

411 DR. GERDES:

Correct.

412 MR. CLARKE:

And by "Carry-over" that is from amplified DNA possibly getting into DNA that is lower in amount and unamplified, correct?

413 DR. GERDES:

Correct.

414 MR. CLARKE:

Is it correct that contamination is just as big a problem at your laboratory as it is in forensic laboratories?

415 DR. GERDES:

I don't believe that is true, because of the nature of the specimens that are handled and the way they are handled in forensic labs.

416 MR. CLARKE:

Well, you have contamination in your own laboratory, don't you?

417 DR. GERDES:

Occasionally we will see that, yes.

418 MR. CLARKE:

Do you feel you have a pretty good handle on contamination at your laboratory?

419 DR. GERDES:

Yes. There is a number of differences in the way we handle contamination in a clinical lab as well as the nature of the specimens and that entire board that we talked about.

420 MR. CLARKE:

Excuse me, objection. Nonresponsive, your Honor.

421 THE COURT:

Overruled. The answer will remain. Ask another question.

422 MR. CLARKE:

Dr. Gerdes, with respect to your laboratory, do you continue to offer services to clients, despite these instances of contamination that occur?

423 DR. GERDES:

Yes.

424 MR. CLARKE:

Incidentally, when you are given a sample, how do you receive it?

425 DR. GERDES:

It is received as a sterile blood specimen.

426 MR. CLARKE:

Okay.

427 DR. GERDES:

Or--

428 MR. CLARKE:

You are referring to the actual mechanical manner. How do samples get to your laboratory from somewhere else?

429 DR. GERDES:

They are transported by a courier.

430 MR. CLARKE:

Do you receive any samples that are not transferred by a courier?

431 DR. GERDES:

There are some mailed in.

432 MR. CLARKE:

By what, a package service or a shipment service?

433 DR. GERDES:

Yes. Fed ex or whatever, yes.

434 MR. CLARKE:

Are they packed under ice?

435 DR. GERDES:

Most are not; some might be.

436 MR. CLARKE:

Where could they be coming from? Where do they come from?

437 DR. GERDES:

They come from a variety of hospitals and other sources.

438 MR. CLARKE:

How long a period of time can it be from when that sample is removed from a patient to the time your laboratory receives it?

439 DR. GERDES:

It is recorded in terms of the request form as to when it was drawn and when it is received. It can be up to a day or two.

440 MR. CLARKE:

Is it ever any longer than a day or two?

441 DR. GERDES:

Yes.

442 MR. CLARKE:

How long could it be?

443 (No audible response.)
444 MR. CLARKE:

Or can it be?

445 DR. GERDES:

Well, one of the processes that occurs when a sample arrives in the lab is you--the first thing the technician does is they look at that time, and if it is too long, they will reject the specimen.

446 MR. CLARKE:

What is too long?

447 DR. GERDES:

It depends on the type of test.

448 MR. CLARKE:

Okay. What would be--I'm trying to think in terms of the testing that you do and let's take CMV.

449 DR. GERDES:

Okay.

450 MR. CLARKE:

At what time period would a sample be rejected?

451 DR. GERDES:

In that particular case the DNA of that virus is relatively stable and in a blood specimen that is stored at ambient temperature I would say somewhere on the order of five or six days we would still see no real decrease in the amount of DNA that we could detect to allow is to find that virus.

452 MR. CLARKE:

And at the five or six-day period that would be unrefrigerated for those five or six days?

453 DR. GERDES:

Yes.

454 MR. CLARKE:

You continue to go ahead and use that sample for casework typing?

455 DR. GERDES:

Yes, because we've done previous validation studies to show or assure ourselves that that specimen is still adequate at that point, as long as it is sterile, undamaged, labeled.

456 MR. CLARKE:

In other words, as long the DNA hasn't degraded to the point of not being able to obtain a result, then it is okay to use it?

457 MR. SCHECK:

Objection, that misstates the testimony.

458 THE COURT:

Overruled.

459 DR. GERDES:

You have to remember, blood that is in a sterile blood specimen like that is really fairly--it is not going to degrade, it is not contaminated with bacteria, and it is a different--difference why you would--eventually it would degrade, but basically the problem is the cells that are in that blood specimen, if for instance if we are going to do HLA typing, we need those within 24 hours because the cells start to die and it is not a degradation process. There are other complications as to why and it is specific to each test as to why that specimen would be appropriate not.

460 MR. CLARKE:

You described yesterday the fact that in your view other--strike that. You described yesterday that a forensic protocol required that reference samples be separate in time as far as their extraction of DNA, twenty to thirty minutes from evidence samples. Do you recall that testimony?

461 DR. GERDES:

Yes, yes.

462 MR. CLARKE:

Do you recall also describing that after a reference sample has had DNA extracted from it, that there should be a clean-up with bleach of that area where that is taking place and then evidence samples can be extracted? Do you recall that testimony?

463 MR. SCHECK:

Objection, misstates the testimony in terms of the specifics.

464 THE COURT:

Overruled.

465 DR. GERDES:

I recall that testimony.

466 MR. CLARKE:

What forensic protocol says that?

467 DR. GERDES:

That all--all--the Twgdam guidelines and a variety of protocols from individual labs that I have read specifically state that reference samples should be handled at a separate time and place than the evidence items.

468 MR. CLARKE:

But as far as this procedure of reference samples, cleaning the area with bleach and then extracting DNA from evidence samples, what forensic protocol requires that?

469 DR. GERDES:

Well, it is amazing. None of them say it that specifically. Those are pretty common sense things, though, if you are a microbiologist.

470 MR. CLARKE:

Objection, move to strike, your Honor.

471 THE COURT:

Overruled.

472 DR. GERDES:

Someone who knows about the sensitivity of PCR. I think those are common sense things that you would do.

473 MR. CLARKE:

Dr. Gerdes, what forensic protocol says to do those things?

474 DR. GERDES:

There is no forensic protocol that specifically says to do those things.

KEY QUOTE
475 MR. CLARKE:

When you testified yesterday that a forensic protocol requires that, then were you mistaken?

476 MR. SCHECK:

Misstates the testimony.

477 THE COURT:

Sustained. Rephrase the question.

478 MR. CLARKE:

You described yesterday that a forensic protocol required those steps. Was that then not the case?

479 DR. GERDES:

Basically what I was referring to was the fact that forensic protocols, numerous forensic protocols state that you should handle the reference samples at a separate time and place that evidence items or large amounts of DNA separate than small amounts. And I would have to look in detail in the user guide. I believe there--there is a section in there that discusses these kind of things in the user guide in terms of cleaning up.

480 MR. CLARKE:

Dr. Gerdes, isn't it wiser to extract evidence samples first before reference samples?

481 DR. GERDES:

The main factor you have to keep in mind is to separate them both in time and space. If you are going to be handling them within a fairly close time, it would be advisable to handle the lower concentration specimen before the larger, so in that case, yes.

482 MR. CLARKE:

In other words, it would be better to extract DNA from evidence samples first because of their potential for having low DNA amounts and then reference samples later because they have higher DNA amounts, correct?

483 DR. GERDES:

Yes.

484 MR. CLARKE:

What order was that done in by the Los Angeles Police Department in this case?

485 DR. GERDES:

As far as the handling, the reference sample was handled first. As far as the extraction, it was in the opposite order where the reference sample was handled last.

486 MR. CLARKE:

Dr. Gerdes, isn't it true that Collin Yamauchi extracted the evidence first before the known samples in this case?

487 DR. GERDES:

As far as the extraction, yes. As far as the handling, no.

488 MR. CLARKE:

As far as the extraction of DNA by Collin Yamauchi in the serology room that you have described by photograph, he extracted the lower DNA amount samples first, didn't he?

489 DR. GERDES:

Yes, he did.

490 MR. CLARKE:

He extracted high DNA samples last, didn't he?

491 DR. GERDES:

Yes, he did.

492 MR. CLARKE:

Incidentally, did you ever test any mixed samples in your laboratory?

493 DR. GERDES:

No.

494 MR. CLARKE:

Have you ever conducted any lab--I'm sorry--any testing in your laboratory involving, for instance, amniotic fluid cells?

495 DR. GERDES:

Yes.

496 MR. CLARKE:

What is amniotic fluid?

497 DR. GERDES:

Well, it is the fluid that surrounds the baby and it is used for diagnosis of prenatal--prenatal diagnosis.

498 MR. CLARKE:

In other words, you are looking to find out if a fetus will suffer from any diseases, correct?

499 DR. GERDES:

Correct.

500 MR. CLARKE:

In that process you are attempting to make a clinical diagnosis of whether or not an unborn child will contract, let's say, cystic fibrosis?

501 DR. GERDES:

Yes.

502 MR. CLARKE:

That testing was formerly conducted in your laboratory?

503 DR. GERDES:

We have conducted testing not on the amniotic fluid itself, but we have conducted testing on cells that were grown from that fluid.

504 MR. CLARKE:

Do you continue to do that in your laboratory?

505 DR. GERDES:

Occasionally.

506 MR. CLARKE:

When that type of material is removed from the patient, the pregnant mother, doesn't that material contain a mixture of cells from two different people?

507 DR. GERDES:

It can.

508 MR. CLARKE:

And in fact it can contain a mixture of cells from the pregnant mother?

509 DR. GERDES:

Yes.

510 MR. CLARKE:

And it can contain a mixture of cells from the fetus which is the cellular material you are trying to test, correct?

511 DR. GERDES:

That's correct.

512 MR. CLARKE:

And you have to, in terms of that testing, separate those cells out, don't you?

513 DR. GERDES:

Yes. And in that particular instance you know who the mother is and so that allows you to eliminate that--that source.

514 MR. CLARKE:

Isn't that similar to a sexual assault victim in a criminal case who has been raped?

515 DR. GERDES:

It is in some ways, yes.

516 MR. CLARKE:

And there is a mixture of cellular material in that type of sample as well?

517 DR. GERDES:

Yes.

518 MR. CLARKE:

Yesterday you described the fact that in theory a single cell, one cell from a person, a human, could be copied using PCR. Do you recall that?

519 DR. GERDES:

Yes.

520 MR. CLARKE:

When you stated that in theory, isn't it correct that there are laboratories that do copy single cells outside forensics?

521 DR. GERDES:

Single cells?

522 MR. CLARKE:

Yes.

523 DR. GERDES:

Yes, there are labs who have done that and it is not something that is--it is not very many labs, but there are labs who can do that.

524 MR. CLARKE:

It is not done in forensics, correct?

525 DR. GERDES:

That's correct.

526 MR. CLARKE:

Because one cell is not very much DNA, correct?

527 DR. GERDES:

That's correct.

528 MR. CLARKE:

Isn't it true that the problem of contamination depends to a large extent on how small a sample one is trying to amplify?

529 DR. GERDES:

Yes. The problem of contamination is increased with a smaller sample.

530 MR. CLARKE:

For instance, in typing a single cell, a scientist would have to be extraordinarily careful about contamination, correct?

531 DR. GERDES:

Yes.

532 MR. CLARKE:

And in fact copying one cell would be presumably what, the height of sensitivity to contamination problems that a scientist could have?

533 DR. GERDES:

Yes, but they are not typing a single cell from a crime scene. They are--they are typing single cells in a controlled laboratory environment where they can dilute that down with sterile material and know what they started with.

534 MR. CLARKE:

So contamination isn't a problem for that type of sample with one cell?

535 DR. GERDES:

It is a problem. It is a problem anywhere.

536 MR. CLARKE:

It is an important problem for someone trying to copy very small numbers of cells, correct?

537 DR. GERDES:

Yes.

538 MR. CLARKE:

One was a very small number, correct?

539 DR. GERDES:

Yes.

540 MR. CLARKE:

At your laboratory your tests using PCR start with different numbers of cells that are present in a sample; is that correct?

541 DR. GERDES:

The PCR tests that we use we adjust the DNA concentrations to higher concentrations that would generally be used, relatively speaking, in a forensic setting, and the reason we do that is to avoid as much as we can the contamination problem.

542 MR. CLARKE:

So you set--you made a decision at what level of the number of cells in a sample, before you are willing to use PCR to obtain results that you will report in casework?

543 DR. GERDES:

Yes.

544 MR. CLARKE:

You have described your laboratory as being capable of detecting as few as one to five cells in a sample, haven't you?

545 DR. GERDES:

One to five cells?

546 MR. CLARKE:

Correct.

547 DR. GERDES:

What kind of cells?

548 MR. CLARKE:

DNA, copies of target DNA, and we will define those terms.

549 DR. GERDES:

The initial PCR that we did was just for CMV. Initial studies were adjusted to--for us to be capable of detecting one to five copies of that particular virus. Is that what you are referring to?

550 MR. CLARKE:

All right. Well, what does target DNA mean?

551 DR. GERDES:

Well, the gene you are looking for and the virus is not a cell, so if we are looking for a virus, you are looking for that piece of the virus or sequence of the nucleic acid of the virus and that would be defined as the target. The target is the virus and the amount we would be able to detect would be between one and five.

552 MR. CLARKE:

That is again a very low level of DNA, correct?

553 DR. GERDES:

That's correct.

554 MR. CLARKE:

You then utilized a higher number of--number of cells in this CMV testing, correct?

555 DR. GERDES:

It is not cells. It is adjusted to the higher number of copies detectable with the PCR system of the virus; not a cell.

556 MR. CLARKE:

All right. Did you in fact adjust it to a higher number of copies to use in your testing?

557 DR. GERDES:

Yes. The initial studies again on the transplant patients where we looked at the CMV, if we use that kind of sensitivity where we found one to five cells, we were finding it frequently in all of the patients and it wasn't giving us any clinically relevant information, so we adjusted the technique--well, we did this study--a four-year study to determine what was the relevant amount that would allow us to identify patients that needed to be treated as opposed to those who had asymptomatic shedding, then we adjusted the amount so that it would be in that clinically relevant range so that the testing would be useful for patients.

558 MR. CLARKE:

What threshold level do you use now before you will amplify?

559 DR. GERDES:

As far as virus--the CMV virus?

560 MR. CLARKE:

Yes.

561 DR. GERDES:

Our sensitivity is around 50 copies.

562 MR. CLARKE:

50 copies of this target DNA?

563 DR. GERDES:

Yes.

564 MR. CLARKE:

As far as forensic testing and in particular this case, are you familiar with the number of cycles used by the Los Angeles Police Department when they go through this amplification process?

565 DR. GERDES:

Yes, I am.

566 MR. CLARKE:

And how many cycles is that?

567 DR. GERDES:

32.

568 MR. CLARKE:

Is that in fact the number recommended by Roche in the user guide?

569 DR. GERDES:

It is.

570 MR. CLARKE:

Are you familiar with the number of cycles used by Cellmark in this case?

571 DR. GERDES:

They use 32.

572 MR. CLARKE:

Are you familiar with the number of cycles used by the Department of Justice?

573 DR. GERDES:

They use 32 also.

574 MR. CLARKE:

All three laboratories use the recommended number of cycles recommended by the manufacturer?

575 DR. GERDES:

That's correct.

576 MR. CLARKE:

Far as sensitivity levels isn't it the case that with regard or forensic testing that there are certain sensitivity levels of starting DNA, that is, the amount of starting DNA, that are recommended?

577 DR. GERDES:

Yes.

578 MR. CLARKE:

Is it also the case that these numbers of cycles play a role in the ability to copy DNA and obtain results?

579 DR. GERDES:

Yes.

580 MR. CLARKE:

What role do they play?

581 (No audible response.)
582 MR. CLARKE:

That is the number of cycles?

583 DR. GERDES:

Well, in the process this Xeroxing of--molecular Xeroxing of a copy of that, it is basically how long you let the Xerox machine run. If you go--each time you double the amount of DNA and you go 32 cycles, then you have a certain level of amplification ability or copying ability. If you go more cycles, what happens is then just like you leave the Xerox machine on longer, you are going to get more copies, and the longer--the more cycles, the more DNA you are going to make within limits. I mean, eventually you get--it runs out of the things it needs, the building blocks it needs to make DNA, and the whole thing stops.

584 MR. CLARKE:

If anyone--if I were to start a DNA laboratory and I programmed that machine to amplify, say, a bloodstain 50 cycles, would that be a mistake?

585 DR. GERDES:

Depends on what you are trying to do in terms of protocol. Certainly it would be an increased risk of amplifying very small amounts of material and having them become a contaminant.

586 MR. CLARKE:

So the number of cycles becomes important in controlling contamination?

587 DR. GERDES:

Yes.

588 MR. CLARKE:

And in fact 32, that wasn't a number picked on a board, that is, a dart thrown at a board; isn't that right?

589 DR. GERDES:

That's right.

590 MR. CLARKE:

And in fact wasn't the no. 32 arrived at by scientific experimentation and demonstration of the appropriate number of cycles to use?

591 DR. GERDES:

It is the appropriate number of cycles to use for two nanograms of DNA, which is what the user guide recommends as far as a starting amount.

592 MR. CLARKE:

Well, isn't it correct that these methods have been shown to produce accurate and reliable results using less than two nanograms of starting DNA?

593 DR. GERDES:

I haven't seen any published detailed studies. There are people who claim that and there are phraseology in certain papers where that is claimed, but I think that there are certain dangers that occur when you get down much below--certainly below a half a nanogram.

594 MR. CLARKE:

You've described reading the user guide, correct?

595 DR. GERDES:

Yes.

596 MR. CLARKE:

And the user guide describes using--I'm sorry--using amounts less than two nanograms as producing accurate and reliable results, correct?

597 DR. GERDES:

I think there is a phrase in there that says something to the effect that it is possible in an experienced laboratory to possibly type less than that. They don't give an exact amount, how much less, but that phrase is in there.

598 MR. CLARKE:

Hasn't the scientific literature demonstrated typeable amounts, that is, amounts producing accurate and reliable results far below two nanograms?

599 DR. GERDES:

I haven't seen any paper that goes to a detailed study of tremendously smaller amounts.

600 (Discussion held off the record between the Deputy District Attorneys.)
601 MR. CLARKE:

All right. Your Honor, I would like to shift subjects and I just inquiring on when the Court was going to take a break?

602 THE COURT:

Three o'clock.

603 MR. CLARKE:

Very well. I have a--well, let me ask a couple questions first.

604 MR. CLARKE:

In the timing process using PCR, it is important to use controls, correct?

605 DR. GERDES:

That's correct.

606 MR. CLARKE:

And you described controls yesterday; is that right?

607 DR. GERDES:

Yes.

608 MR. CLARKE:

Controls are used in this typing process to tell whether or not the test is working correctly?

609 DR. GERDES:

That's the purpose of controls.

610 MR. CLARKE:

All right. Your Honor, I have an eight-and-a-half-by-eleven piece of paper that I would ask to be marked as--

611 THE CLERK:

557.

612 THE COURT:

557.

613 MR. CLARKE:

557, a copy of which I provided to counsel previously.

614 (Peo's 557 for id = document)
615 MR. CLARKE:

And with the Court's permission, I would like to use that on the elmo.

616 THE COURT:

Proceed.

617 MR. CLARKE:

And Dr. Gerdes, can you--I don't know if it is easier for you to use the monitor to your right.

618 DR. GERDES:

I would prefer to look from down there if that is okay.

619 MR. CLARKE:

Sure. That's fine. First of all, you have described previously your examination of various materials from the Los Angeles Police Department, correct?

620 DR. GERDES:

That's correct.

621 MR. SCHECK:

Your Honor, may I just make a suggestion about positioning, because in this fashion the witness' back is to part of the jury.

622 THE COURT:

Yes. Thank you.

623 MR. CLARKE:

And in fact you were and have taken the opportunity to review the testing conducted by the Los Angeles Police Department in their DNA laboratory in this case, correct?

624 DR. GERDES:

That's correct.

625 MR. CLARKE:

And with regard to that testing, you have also described yesterday having reviewed materials from the DNA laboratory unrelated to this case, correct?

626 DR. GERDES:

Correct.

627 MR. CLARKE:

Now, your review of the DNA typing documents from the Los Angeles Police Department in this case reveals that department's, in particular, Collin Yamauchi's, use of a number of controls, correct?

628 DR. GERDES:

That's correct.

629 MR. CLARKE:

Now, on this particular document that is labeled at the top "Los Angeles Police Department PCR DQ-Alpha testing controls" there is a number "1" and the term "Reagent control." Do you see that?

630 DR. GERDES:

I do.

631 MR. CLARKE:

Then in parenthesis and quotation marks the term "Cloth control."

632 DR. GERDES:

Yes.

633 MR. CLARKE:

First of all, what is a reagent control?

634 DR. GERDES:

This is a control that basically--that is why it is called a cloth control. A piece of cloth or a swab that is unused is basically run through the process, including all of the reagents, buffers, the fluid and so forth that are used in this process, and then you look at a typing, go through the same typing procedure, and ask the question is there any evidence of DNA on that particular control. So it is a control for contaminants that would be introduced into reagents or things that are going on along that process, all the way from the beginning.

635 MR. CLARKE:

Is that an important control to use?

636 DR. GERDES:

I think it is an important control, yes.

637 MR. CLARKE:

Now, there is also the term "Cloth control." Where does that come from?

638 DR. GERDES:

It comes from the fact that you take a piece of cloth that has nothing on it presumably and you run it through the process.

639 MR. CLARKE:

If a reagent control him shows a DNA reaction, for instance, at the ultimate or the last typing phase of the testing process, what does that tell the analyst?

640 DR. GERDES:

It tells the analyst that at some time, either in handling that cloth or going through all of this process from the very beginning to the end, DNA has been introduced.

641 MR. CLARKE:

That is one control, reagent control or cloth control, as it is also called, correct?

642 DR. GERDES:

That's correct.

643 MR. CLARKE:

That is a control utilized by the Los Angeles Police Department not only in their casework in this case, but also in all the other typing that they conducted that you've described yesterday?

644 DR. GERDES:

That's correct.

645 MR. CLARKE:

The second control, labeled "Amplification control positive," what is that?

646 DR. GERDES:

That generally refers to the DNA that is incorporated as part of the kit, so the company that sells this kit has a positive DNA sample. It is a 1.1, 4 type and it is incorporated in the PCR process just to ensure that the individual who uses the kit can amplify the DNA and that the strips are working appropriately so that that particular control types as a 1.1, 4.

647 MR. CLARKE:

As far as that amplification control, if during this testing process and ultimately at the final end--first of all, are each of those controls actually typed on a strip at the end?

648 DR. GERDES:

Yes.

649 MR. CLARKE:

In other words, they are handled as far as amplification, typing and then the analyst reading the results from the dots just like a regular evidence sample; is that right?

650 DR. GERDES:

That's correct.

651 MR. CLARKE:

Let's say--

652 DR. GERDES:

Well, not strictly correct. On an evidence sample there is a rule with regard to a C dot and in these types of controls that rule no longer holds, because of the fact that any DNA, anything at all, present on these types of controls, indicates that there is human DNA that shouldn't be there that is invisible, so it indicates contamination regardless of what the C is. So as far as typeable, that needs to be clarified.

653 MR. CLARKE:

Okay. We'll return to the C probe. What you have just described applies to certainly, no. 1, the reagent control, correct?

654 DR. GERDES:

Yes.

655 MR. CLARKE:

No. 2, however, what you just said does not apply, correct, because you expect to find the types 1.1 and 4 as well as a C dot reaction, correct?

656 DR. GERDES:

Well, actually it does apply if you find the evidence of another dot other than the 1.1 and 4 dot. Perhaps you find a 2 dot or a 3 dot, then you know that there is foreign DNA that has been incorporated into that positive control. So any indication of those kind of dots on this control indicates contamination.

657 MR. CLARKE:

What I asked, though, Dr. Gerdes, was as far as the C probe is concerned and a reaction, the C probe should show up on the amplification control positive, no. 2?

658 DR. GERDES:

That's true.

659 MR. CLARKE:

And in fact you should see the 1.1 dot, correct?

660 DR. GERDES:

Correct.

661 MR. CLARKE:

And the 4 dot?

662 DR. GERDES:

Correct.

663 MR. CLARKE:

And actually also the 1 dot, correct?

664 DR. GERDES:

Correct.

665 MR. CLARKE:

And one more dot that is also basically reacted to by a 4, correct?

666 DR. GERDES:

The 1.2, 1.3, 4 dot.

667 MR. CLARKE:

Now, let's turn to--while we are on amplification control positive, if that control is a 1.1 and a 4 and all of a sudden there is a 2 dot there, does that signal the analyst to something on that control?

668 DR. GERDES:

It indicates on that control that there is a human DNA that has been contaminated on that strip. There is a 2 dot on that positive control and it shouldn't be there.

669 MR. CLARKE:

With respect to no. 3, what is labeled "Amplification control negative," what is that?

670 DR. GERDES:

This is a control that some people call a water control, and it is incorporated at the stage where you put the sample into the thermalcycler, into the machine that copies things, and that is going to control--basically it is designed to pick up amplification carry-over so if you are going--that product carry-over, this is a stage where that would frequently appear. And so this control is really designed to see if that process, that kind of contamination has occurred.

671 MR. CLARKE:

In other words, that is to help the analyst determine whether or not something has invaded the typing process that may affect the results, correct?

672 DR. GERDES:

Correct.

673 MR. CLARKE:

Turning to no. 4, "Positive control standard," what is that?

674 DR. GERDES:

This is a known DNA or known specimen. Most laboratories use a blood specimen. They are drawn from individuals who work at the lab, for instance, or known people at least, and then that is run through the entire process of handling and of extracting the DNA and going all the way through until you get a typeable result on that control for whether or not on a random basis using different kind of types you are able to get a typeable result. And it controls for the extraction process, for the amplification process and for the strips themselves to make sure that they are appropriately typing the sample.

675 MR. CLARKE:

Turning to no. 5, a substrate control, what is that?

676 DR. GERDES:

Substrate control--substrate means--that means what something is on, so the typical substrate control would be if you collect a specimen in an area, you would take an adjacent area that doesn't appear to have any obvious blood--if it is a bloodstain, any blood, and you would take a swab from that area and then carry that through the entire process. Now, this is a good control because it goes all the way back to or should at least go all the way back to the crime scene, because if you do that at the crime scene and you carry it through in parallel all the way through, it should tell you not only how much DNA was just sort of like the background DNA in that area at the crime scene, but it also tells you whether during the manipulations, assuming everything was done in parallel, whether during the manipulations that human--any foreign human DNA might have been incorporated.

677 MR. CLARKE:

Dr. Gerdes, that substrate control is an excellent control, isn't it?

678 DR. GERDES:

Well, it is an excellent control in terms of determining background level of DNA as long as--in my opinion it should be altered. I mean, basically it doesn't have a stabilizer in there, and I think it could be improved upon, but it is an excellent control.

679 MR. CLARKE:

You have previously described the substrate control as used in forensics as an excellent control, haven't you?

680 DR. GERDES:

I--yes.

681 MR. CLARKE:

Now, with regard to, and lastly, the C probe, you discussed that a few moments ago. That is a probe, is it not, used to help guide the analyst in interpreting results as revealed by reactions on the strips?

682 DR. GERDES:

The C probe?

683 MR. CLARKE:

Correct.

684 DR. GERDES:

The C probe is the least amount of DNA on the strip. It tells you whether there is adequate DNA to proceed with the typing result. If the C probe is not present, you don't have enough DNA to type. It is--but the probe--this particular C probe fails as a control if you are dealing with mixtures because in the case of a mixture you don't know what proportion one contributor and the second--the proportion of the different contributors. If there are two contributors, one may have a large amount of DNA adequate to light up the C dot and one may have a small amount of DNA which by itself probably would not have lit up the C dot, but gives you faint detectable signals.

685 MR. CLARKE:

Just a couple of questions if I might, your Honor, on this.

686 MR. CLARKE:

All of these controls were used by the Los Angeles Police Department in this case, correct?

687 DR. GERDES:

Yes, they were.

688 MR. CLARKE:

Those controls were used by Cellmark in this case?

689 DR. GERDES:

Yes.

690 MR. CLARKE:

Those controls were used by the Department of Justice in this case?

691 DR. GERDES:

Yes.

692 MR. CLARKE:

And in fact the Department of Justice uses an additional control what is referred to, and I believe you described it yesterday, their QC sample, correct?

693 DR. GERDES:

Yes.

694 MR. CLARKE:

All right.

Temperature

tense

Key Quotes (5)

Dr. John Gerdes
Again, it is a demonstration paper. What they dealt with in that paper in terms of contamination is one experiment where five tubes were opened on a bench top. They scratched their head over the tubes, closed them up and showed there was no contamination. That is a demonstration.
Gerdes's blanket dismissal of an FBI validation study — his 'demonstration paper' framing became a rhetorical anchor Clarke used to undercut his credibility across all supporting literature.
Dr. John Gerdes
There is no forensic protocol that specifically says to do those things.
Directly contradicted his prior day's testimony that a forensic protocol 'required' specific contamination-prevention procedures, a significant concession that Clarke had been building toward.
Dr. John Gerdes
No, I haven't published in the forensic area.
Established that the expert who dismissed all forensic DNA publications as insufficient 'demonstration papers' has never himself published in the field he is critiquing.
Dr. John Gerdes
I consider that publication a one-sided slant on the cases. It discusses a number of cases, several of which I have been involved with, where there were highly contested issues which are not discussed in that article.
Revealed Gerdes's personal antagonism toward Ed Blake's forensic PCR publication, suggesting his critique goes beyond scientific methodology to prior adversarial history.
Dr. John Gerdes
My function was to look simply at the science involved and the data involved in PCR.
Gerdes defended not reviewing serological results, which Clarke used to argue his contamination opinions were based on incomplete analysis of the case evidence.

Evidence (9)

Informal
Book 'PCR Technology' edited by Henry Erlich, including chapter 'Applications of PCR to the analysis of biological evidence' co-authored by Erlich, von Beroldingen, Higuchi, Sensabaugh, and Blake
discussed, Gerdes characterized as review article not establishing validity
Informal
Ed Blake et al., 'PCR amplification and HLA DQ-Alpha oligonucleotide typing on biological evidence samples: Casework experience'
discussed, Gerdes rejected as one-sided due to personal involvement in contested cases it omitted
Informal
Russell Higuchi et al., 'DNA typing from single hairs'
discussed, Gerdes characterized as demonstration paper not addressing routine forensic application
Informal
Henry Lee et al., 'Genetic markers in human bone: I, DNA analysis' (including Cellmark authors Herrin and Garner)
discussed, Gerdes characterized as controlled-conditions demonstration not addressing lab contamination
Informal
Comey and Budowle (FBI), 'Validation studies on the analysis of the HLA DQ-Alpha locus using PCR'
discussed, Gerdes dismissed contamination findings as based on only five tubes, inadequate to conclude contamination is not an issue
Informal
Herrin, Fildes, Reynolds, 'Evaluation of the amplitype PM DNA test system on forensic case samples'
discussed, Gerdes noted one false match among 16 samples, characterized as demonstration paper
+ 3 more

Notable Exchanges (4)

George ClarkeDr. John Gerdes
Clarke walked Gerdes through approximately seven peer-reviewed publications supporting DQ-Alpha, PM, and D1S80 reliability; Gerdes dismissed every single one as a 'demonstration paper.' Clarke then noted Gerdes has never published in the forensic field himself, leaving him in the position of critiquing a literature he has not contributed to.
strategic
George ClarkeDr. John Gerdes
Clarke pressed Gerdes on his prior-day testimony that a 'forensic protocol required' specific contamination-prevention steps (bleaching, timing of reference vs. evidence extraction). After sustained objection battles, Gerdes conceded: 'There is no forensic protocol that specifically says to do those things,' attributing it to common sense rather than any written requirement.
revealing
George ClarkeDr. John Gerdes
Clarke established that Gerdes never reviewed the serological results in the case and that no member of the defense team ever discussed them with him. When Clarke asked whether, as a scientist, he would want all results on a bloodstain, Gerdes said 'I'm sure they are' important — but maintained it was outside his assigned scope.
strategic
George ClarkeDr. John Gerdes
Clarke confirmed that Collin Yamauchi actually extracted evidence samples before known (reference) samples — the correct order according to Gerdes's own stated principle of extracting lower-DNA samples first. Gerdes distinguished 'handling' from 'extraction,' but conceded the extraction order was as Clarke described.
revealing

Credibility Attacks (5)

⚔ Dr. John Gerdes
limited personal experience
Clarke established Gerdes had run fewer than 100 polymarker samples in his career (a single kit, partially used), had never used the D1S80 kit at all, and had never attended any lectures or presentations on forensic PCR typing.
⚔ Dr. John Gerdes
prior inconsistent statement
Clarke impeached Gerdes on his prior-day testimony that a forensic protocol 'required' specific contamination-prevention procedures; Gerdes ultimately admitted no forensic protocol specifically requires those steps.
⚔ Dr. John Gerdes
selective analysis / incomplete review
Clarke highlighted that Gerdes formed opinions on cross-contamination of bloodstains without ever reviewing the serological results on those same stains, and that the defense never shared those results with him.
⚔ Dr. John Gerdes
bias / personal antagonism
Gerdes revealed he rejected Ed Blake's forensic casework publication not on methodological grounds alone, but because he had been personally involved in contested cases the article omitted — suggesting a pre-existing adversarial relationship with the prosecution's DNA methodology community.
⚔ Dr. John Gerdes
tu quoque / laboratory practice inconsistency
Clarke established that Gerdes's own lab continues operating despite contamination incidents, uses non-FDA-approved tests, accepts samples unrefrigerated for up to five or six days, and receives specimens by FedEx — practices analogous to those Gerdes criticized in forensic labs.

Witness Demeanor

(No audible response.) — when asked how long samples could sit before reaching his lab
(Brief pause.) — after being shown the Herrin PM paper to review

Objections

13 objections (3 sustained, 9 overruled)
Proceeding 7950 • 694 utterances • Defense witness
Criminal Trial
Department 103
⚖️ Start
📂 AUG 3, 1995 📄 Cross-examination of Dr. John
AUG 3, 1995 KRT DvH TD